205 related articles for article (PubMed ID: 37557991)
1. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
[TBL] [Abstract][Full Text] [Related]
4. Zuranolone and its role in treating major depressive disorder: a narrative review.
Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D
Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of zuranolone in postpartum depression and major depressive disorder: a review & number needed to treat (NNT) analysis.
Cha DS; Kleine N; Teopiz KM; Di Vincenzo JD; Ho R; Galibert SL; Samra A; Zilm SPM; Cha RH; d'Andrea G; Gill H; Ceban F; Meshkat S; Wong S; Le GH; Kwan ATH; Rosenblat JD; Rhee TG; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2024; 25(1):5-14. PubMed ID: 38164653
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
[No Abstract] [Full Text] [Related]
8. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
[TBL] [Abstract][Full Text] [Related]
9. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
[TBL] [Abstract][Full Text] [Related]
10. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
[TBL] [Abstract][Full Text] [Related]
11. Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
[TBL] [Abstract][Full Text] [Related]
12. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
[TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder.
Cutler AJ; Mattingly GW; Maletic V
Transl Psychiatry; 2023 Jun; 13(1):228. PubMed ID: 37365161
[TBL] [Abstract][Full Text] [Related]
14. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
[TBL] [Abstract][Full Text] [Related]
15. Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.
Marecki R; Kałuska J; Kolanek A; Hakało D; Waszkiewicz N
Front Psychiatry; 2023; 14():1298359. PubMed ID: 38116383
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials.
Zou J; Yang L; Yang G; Gao J
Psychiatry Res; 2023 Oct; 328():115450. PubMed ID: 37683318
[TBL] [Abstract][Full Text] [Related]
17. Trial of SAGE-217 in Patients with Major Depressive Disorder.
Gunduz-Bruce H; Silber C; Kaul I; Rothschild AJ; Riesenberg R; Sankoh AJ; Li H; Lasser R; Zorumski CF; Rubinow DR; Paul SM; Jonas J; Doherty JJ; Kanes SJ
N Engl J Med; 2019 Sep; 381(10):903-911. PubMed ID: 31483961
[TBL] [Abstract][Full Text] [Related]
18. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of zuranolone in the treatment of major depressive disorder: a meta-analysis.
Wang S; Zhang W; Liu Z; Zhang T; Wang Y; Li W
Front Neurosci; 2023; 17():1332329. PubMed ID: 38292895
[TBL] [Abstract][Full Text] [Related]
20. Distinct mechanisms of allopregnanolone and diazepam underlie neuronal oscillations and differential antidepressant effect.
Takasu K; Yawata Y; Tashima R; Aritomi H; Shimada S; Onodera T; Taishi T; Ogawa K
Front Cell Neurosci; 2023; 17():1274459. PubMed ID: 38259500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
